



COMMERCIAL Products

	Product	Therapeutic Use	Regulatory Status (USDMF / CEP)	Enquire f
<input type="checkbox"/>	Aceclofenac BP / EP	Anti-inflammatory	CEP	
<input type="checkbox"/>	Apixaban	Anti-coagulant	USDMF, EDMF	
<input type="checkbox"/>	Atorvastatin Calcium Crystalline BP/ EP /USP	Anti-hyperlipidemic	USDMF, CEP	
<input type="checkbox"/>	Carbamazepine BP / EP / JP /USP	Anti-Convulsant	USDMF, CEP	
<input type="checkbox"/>	Celecoxib BP / EP /USP	Anti-inflammatory	USDMF, CEP	
<input type="checkbox"/>	Chlorpromazine EP/USP	Antipsychotic	USDMF (Q4 2021), EDMF	
<input type="checkbox"/>	Chlorthalidone EP /USP	Diuretic	USDMF, EDMF	
<input type="checkbox"/>	Clotrimazole BP / EP /USP	Anti-fungal	USDMF, CEP	
<input type="checkbox"/>	Deferasirox	Iron chelating agent	USDMF, CEP filed	
<input type="checkbox"/>	Desvenlafaxine Succinate	Anti depressant	USDMF	
<input type="checkbox"/>	Diclofenac Deanol	Anti-inflammatory	EDMF	
<input type="checkbox"/>	Diclofenac Diethylamine BP	Anti-inflammatory	USDMF, EDMF	^
<input type="checkbox"/>	Diclofenac Epolamine	Anti-inflammatory	USDMF, EDMF	

<input type="checkbox"/>	Diclofenac Free Acid	Anti-inflammatory	USDMF, EDMF
<input type="checkbox"/>	Diclofenac Potassium BP / EP /USP	Anti-inflammatory	USDMF, CEP
<input type="checkbox"/>	Diclofenac Resinate	Anti-inflammatory	EDMF
<input type="checkbox"/>	Diclofenac Salts		
<input type="checkbox"/>	Diclofenac Sodium (BromineFree) BP / EP / JP / USP	Anti-inflammatory	USDMF, CEP
<input type="checkbox"/>	Dihydralazine Sulphate BP /EP	Anti-hypertensive	CEP
<input type="checkbox"/>	Dimethyl Fumarate	Multiple Sclerosis	USDMF, EDMF
<input type="checkbox"/>	Eslicarbazepine	Anti Convulsant	USDMF, EDMF
<input type="checkbox"/>	Hydrochlorothiazide BP / EP / USP	Diuretic	USDMF, CEP
<input type="checkbox"/>	Levetiracetam EP / USP	Anti-Convulsant	USDMF, CEP
<input type="checkbox"/>	Mesalamine / Mesalazine	Anti-inflammatory (IBD)	USDMF, CEP
<input type="checkbox"/>	Mirabegron	Overactive bladder	USDMF, EDMF
<input type="checkbox"/>	Olmesartan Medoxomil EP / USP	Anti-hypertensive	USDMF, CEP
<input type="checkbox"/>	Oxcarbazepine EP / USP	Anti-convulsant	USDMF, CEP
<input type="checkbox"/>	Pirfenidone	Fibrosis	USDMF, CEP
<input type="checkbox"/>	Ranolazine	Anti-anginal	EDMF, USDMF
<input type="checkbox"/>	Rivaroxaban	Anticoagulant	USDMF, CEP filed
<input type="checkbox"/>	Rosuvastatin EP	Anti-hyperlipidemic	USDMF, CEP
<input type="checkbox"/>	Sertraline HCL BP / EP / USP	Anti-depressant	USDMF, CEP
<input type="checkbox"/>	Sildenafil Citrate EP/ USP	Erectile dysfunction	USDMF, CEP
<input type="checkbox"/>	Sitagliptin Phosphate Anhydrous	Diabetes	USDMF
<input type="checkbox"/>	Solifenacin Succinate	Overactive bladder	USDMF, CEP

<input type="checkbox"/>	Succinylcholine / Suxamethonium Chloride	Muscle Relaxant	USDMF, EDMF
<input type="checkbox"/>	Tadalafil EP/ USP	Erectile dysfunction	USDMF, CEP
<input type="checkbox"/>	Ticagrelor	Antiplatelet	DMF
<input type="checkbox"/>	Varenicline Tartarate		USDMF, EDMF
<input type="checkbox"/>	Venlafaxine HCL BP / EP / USP	Anti-depressant	USDMF, CEP

PIPELINE[®] Products

	Product	Therapeutic Use	Regulatory Status (USDMF / CEP)
<input type="checkbox"/>	Apremilast	Psoriasis	Q2 2023
<input type="checkbox"/>	Dapagliflozin Amorphous	Diabetes	Q2 2023
<input type="checkbox"/>	Dapagliflozin Propanediol Monohydrate	Diabetes	Q2 2023
<input type="checkbox"/>	Edoxaban	Anti-coagulant	Q2 2023
<input type="checkbox"/>	Elagolix	Endometriosis	Under development
<input type="checkbox"/>	Empagliflozin	Diabetes	Q3 2023
<input type="checkbox"/>	Linagliptin	Diabetes	Q2 2023
<input type="checkbox"/>	Sacubitril/Valsartan	Heart failure	Q4 2022
<input type="checkbox"/>	Sitagliptin Phosphate Monohydrate	Diabetes	Q2 2023
<input type="checkbox"/>	Vortioxetine Hydrobromide	Anti-depressant	Q2 2023

